ready to launchpad

Photos: Downtown Houston innovation hub in renovated office building opens to the public

Downtown Houston has a new innovation space in Amegy on Main. Photo courtesy of Amegy Bank

Last week, a group of innovators, commercial real estate professionals, and Amegy Bank employees celebrated yet another feat in the Houston innovation ecosystem: another innovative and collaborative space's grand opening.

The Downtown Launchpad is officially open across a few floors in Amegy on Main, a renovated office building on the Southwest side of downtown Houston at 1801 Main St. The grand opening reception was held outside in the building's first floor courtyard adjacent to its upgraded parking garage. The event on May 18 coincided with Houston Tech Rodeo.

"The major renovations to Amegy on Main support our strong Amegy Bank culture and reinforce our commitment to supporting the Houston business, technology and entrepreneur community," says Kelly Foreman, senior vice president and manager of corporate real estate and facilities for Amegy, in a news release. "This space serves as a hub for start-ups and innovation, and the resulting job creation through these incubator programs will continue to be meaningful and impactful for our city."

The renovated space includes:

  • Coworking space managed by The Cannon
  • Accelerator and event space for the Launchpad
  • Main Line Café, a chef-driven restaurant concept open to the public
  • New courtyard
  • First-floor gaming lounge
  • New shared spaces and design elements for the building, such as expanded windows for improved daylight, new furniture, enhanced coffee bars
  • Expanded conference space

Originally announced in October 2019, the Downtown Launchpad opened parts of its upgraded space last fall. Now, the full renovation project is completed, offering a new opportunity for collaboration.

"Amegy on Main has become unlike any other space in Houston," Foreman continues. "We are thrilled to offer this new space, its amenities and business development support to our employees and the expanding innovation community."

Click through some photos of the complete spaces below.

Space for innovation

Photo courtesy of Amegy Bank

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted